Skip to main content
SpringerLink
Log in

Recommended Therapies for Metabolic Defects in Polycystic Ovary Syndrome

  • Chapter
Polycystic Ovary Syndrome

Part of the book series: Contemporary Endocrinology ((COE))

  • 1304 Accesses

Summary

Polycystic ovary syndrome (PCOS) is not just a reproductive condition but has metabolic sequelae. The heterogeneity of the condition is reflected in different emphases in patients on expression of these abnormalities. These conditions include effects on lipids, glucose and insulin metabolism, cardiovascular system and weight control. The metabolic syndrome appears to be more common in PCOS. Treatment of metabolic sequelae can be directed to lifestyle interventions including diet and exercise, insulin-sensitizing drugs and management of hyperlipidaemia. The primary goal of treatment in PCOS is to restore reproductive function while improving metabolic sequelae. This is most readily achieved by reducing insulin resistance through a decrease in weight and abdominal fat. Weight loss and exercise reduce insulin resistance, plasma lipids and blood pressure. In summary, there are a range of diets that may be used in PCOS ranging from high protein to high carbohydrate as well as combinations of glycaemic index (GI) foods. The difference in weight between women from the USA with PCOS and Europe may relate to the extensive use of the Mediterranean-type diet in women from Southern Europe who, while suffering from PCOS, do not appear to get the same metabolic sequelae.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28:341–59.

    Article  PubMed  CAS  Google Scholar 

  2. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46:3–10.

    Article  PubMed  CAS  Google Scholar 

  3. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106:473–81.

    Article  PubMed  CAS  Google Scholar 

  4. Pasquali R, Casimirri F, Venturoli S, et al. Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism 1994; 43:706–13.

    Article  PubMed  CAS  Google Scholar 

  5. Bringer J, Lefebvre P, Boulet F, et al. Body composition and regional fat distribution in polycystic ovarian syndrome. Relationship to hormonal and metabolic profiles. Ann N Y Acad Sci 1993; 687:115–23.

    Article  PubMed  CAS  Google Scholar 

  6. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80:2586–93.

    Article  PubMed  CAS  Google Scholar 

  7. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97:2859–65.

    PubMed  CAS  Google Scholar 

  8. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1:785–9.

    Article  PubMed  CAS  Google Scholar 

  9. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996; 81:2854–64.

    Article  PubMed  CAS  Google Scholar 

  10. Moran L, Norman RJ. Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18:719–36.

    Article  PubMed  CAS  Google Scholar 

  11. Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68:173–9.

    PubMed  CAS  Google Scholar 

  12. Franks S, Mason H, Willis D. Follicular dynamics in the polycystic ovary syndrome. Mol Cell Endocrinol 2000; 163:49–52.

    Article  PubMed  CAS  Google Scholar 

  13. Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999; 13:946–57.

    Article  PubMed  CAS  Google Scholar 

  14. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986; 62:904–10.

    PubMed  CAS  Google Scholar 

  15. Poretsky L, Kalin MF. The gonadotropic function of insulin. Endocr Rev 1987; 8:132–41.

    PubMed  CAS  Google Scholar 

  16. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72:83–9.

    PubMed  CAS  Google Scholar 

  17. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335:617–23.

    Article  PubMed  CAS  Google Scholar 

  18. Jakubowicz DJ, Nestler JE. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab 1997; 82:556–60.

    Article  PubMed  CAS  Google Scholar 

  19. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20:535–82.

    Article  PubMed  CAS  Google Scholar 

  20. Dale PO, Tanbo T, Vaaler S, Abyholm T. Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertil Steril 1992; 58:487–91.

    PubMed  CAS  Google Scholar 

  21. Ovesen P, Moller J, Ingerslev HJ, et al. Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1993; 77:1636–40.

    Article  PubMed  CAS  Google Scholar 

  22. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 2005; 54:1914–25.

    Article  PubMed  CAS  Google Scholar 

  23. Carnevale Schianca GP, Sainaghi PP, Castello L, Rapetti R, Limoncini AM, Bartoli E. Comparison between HOMA-IR and ISI-gly in detecting subjects with the metabolic syndrome. Diabetes Metab Res Rev 2006; 22:111–7.

    Article  PubMed  CAS  Google Scholar 

  24. Holte J, Bergh T, Berne C, Berglund L, Lithell H. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 1994; 78:1052–8.

    Article  PubMed  CAS  Google Scholar 

  25. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595–607.

    Article  PubMed  CAS  Google Scholar 

  26. Reisin E, Alpert MA. Definition of the metabolic syndrome: current proposals and controversies. Am J Med Sci 2005; 330:269–72.

    Article  PubMed  Google Scholar 

  27. Korhonen S, Hippelainen M, Niskanen L, Vanhala M, Saarikoski S. Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. Am J Obstet Gynecol 2001; 184:289–96.

    Article  PubMed  CAS  Google Scholar 

  28. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003; 52:908–15.

    Article  PubMed  CAS  Google Scholar 

  29. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:1929–35.

    Article  PubMed  CAS  Google Scholar 

  30. Faloia E, Canibus P, Gatti C, et al. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest 2004; 27:424–9.

    PubMed  CAS  Google Scholar 

  31. Wu X, Lu K, Su Y. [Renin-angiotensin system: involvement in polycystic ovarian syndrome]. Zhonghua Fu Chan Ke Za Zhi 1997; 32:428–31.

    PubMed  CAS  Google Scholar 

  32. Li X, Shen H, Ge X. [Changes of plasma renin activity and angiotensin II levels in women with polycystic ovary syndrome]. Zhonghua Fu Chan Ke Za Zhi 2000; 35:586–7.

    PubMed  CAS  Google Scholar 

  33. Morris RS, Wong IL, Hatch IE, Gentschein E, Paulson RJ, Lobo RA. Prorenin is elevated in polycystic ovary syndrome and may reflect hyperandrogenism. Fertil Steril 1995; 64:1099–103.

    PubMed  CAS  Google Scholar 

  34. Jaatinen TA, Matinlauri I, Anttila L, Koskinen P, Erkkola R, Irjala K. Serum total renin is elevated in women with polycystic ovarian syndrome. Fertil Steril 1995; 63:1000–4.

    PubMed  CAS  Google Scholar 

  35. Hacihanefioglu B, Seyisoglu H, Karsidag K, et al. Influence of insulin resistance on total renin level in normotensive women with polycystic ovary syndrome. Fertil Steril 2000; 73:261–5.

    Article  PubMed  CAS  Google Scholar 

  36. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985; 61:946–51.

    PubMed  CAS  Google Scholar 

  37. Slowinska-Srzednicka J, Zgliczynski S, Wierzbicki M, et al. The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. J Endocrinol Invest 1991; 14:569–75.

    PubMed  CAS  Google Scholar 

  38. Maitra A, Pingle RR, Menon PS, Naik V, Gokral JS, Meherji PK. Dyslipidemia with particular regard to apolipoprotein profile in association with polycystic ovary syndrome: a study among Indian women. Int J Fertil Womens Med 2001; 46:271–7.

    PubMed  CAS  Google Scholar 

  39. Rajkhowa M, Neary RH, Kumpatla P, et al. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:3389–94.

    Article  PubMed  CAS  Google Scholar 

  40. Dunaif A. Hyperandrogenemia is necessary but not sufficient for polycystic ovary syndrome. Fertil Steril 2003; 80:262–3.

    Article  PubMed  Google Scholar 

  41. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38:1165–74.

    Article  PubMed  CAS  Google Scholar 

  42. Grimaldi A, Heurtier A. [Epidemiology of cardio-vascular complications of diabetes]. Diabetes Metab 1999; 25 Suppl 3:12–20.

    PubMed  CAS  Google Scholar 

  43. Legro RS. Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28:99–109.

    Article  PubMed  CAS  Google Scholar 

  44. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141–6.

    Article  PubMed  CAS  Google Scholar 

  45. Pelusi B, Gambineri A, Pasquali R. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol 2004; 56:41–51.

    PubMed  CAS  Google Scholar 

  46. Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet 2001; 75:177–84.

    Article  PubMed  CAS  Google Scholar 

  47. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001; 16:1995–8.

    Article  PubMed  CAS  Google Scholar 

  48. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:48–53.

    Article  PubMed  CAS  Google Scholar 

  49. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005; 90:3236–42.

    Article  PubMed  CAS  Google Scholar 

  50. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84:165–9.

    Article  PubMed  CAS  Google Scholar 

  51. Talbott EO, Zborowski JV, Boudreaux MY, McHugh-Pemu KP, Sutton-Tyrrell K, Guzick DS. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89:6061–7.

    Article  PubMed  CAS  Google Scholar 

  52. Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89:2160–5.

    Article  PubMed  CAS  Google Scholar 

  53. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86:2453–5.

    Article  PubMed  CAS  Google Scholar 

  54. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89:5592–6.

    Article  PubMed  CAS  Google Scholar 

  55. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006; 21:1426–31.

    Article  PubMed  CAS  Google Scholar 

  56. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003; 80:123–7.

    Article  PubMed  Google Scholar 

  57. Taponen S, Martikainen H, Jarvelin MR, et al. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. J Clin Endocrinol Metab 2003; 88:141–7.

    Article  PubMed  CAS  Google Scholar 

  58. Mohlig M, Spranger J, Osterhoff M, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150:525–32.

    Article  PubMed  Google Scholar 

  59. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996; 45:623–9.

    Article  CAS  Google Scholar 

  60. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998; 69:236–41.

    Article  PubMed  CAS  Google Scholar 

  61. Landin K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 39:1044–8.

    Article  PubMed  CAS  Google Scholar 

  62. Cibula D, Sindelka G, Hill M, Fanta M, Skrha J, Zivny J. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Hum Reprod 2002; 17:76–82.

    Article  PubMed  CAS  Google Scholar 

  63. Orbetzova MM, Shigarminova RG, Genchev GG, et al. Role of 24-hour monitoring in assessing blood pressure changes in polycystic ovary syndrome. Folia Med (Plovdiv) 2003; 45:21–5.

    Google Scholar 

  64. Vrbikova J, Cifkova R, Jirkovska A, et al. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod 2003; 18:980–4.

    Article  PubMed  CAS  Google Scholar 

  65. Norman RJ, Noakes M, Wu R, Davies MJ, Moran L, Wang JX. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 2004; 10:267–80.

    Article  PubMed  Google Scholar 

  66. Norman RJ, Clark AM. Obesity and reproductive disorders: a review. Reprod Fertil Dev 1998; 10:55–63.

    Article  PubMed  CAS  Google Scholar 

  67. Legro RS. Polycystic ovary syndrome and cardiovascular disease: A premature association? Endocr Rev 2003; 24:302–12.

    Article  PubMed  Google Scholar 

  68. Lakhani K, Leonard A, Seifalian AM, Hardiman P. Microvascular dysfunction in women with polycystic ovary syndrome. Hum Reprod 2005; 20:3219–24.

    Article  PubMed  CAS  Google Scholar 

  69. Kravariti M, Naka KK, Kalantaridou SN, et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:5088–95.

    Article  PubMed  CAS  Google Scholar 

  70. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001; 86:4666–73.

    Article  PubMed  CAS  Google Scholar 

  71. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005; 152:749–56.

    Article  PubMed  CAS  Google Scholar 

  72. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51:581–6.

    Article  PubMed  CAS  Google Scholar 

  73. Solomon CG, Hu FB, Dunaif A, et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001; 286:2421–6.

    Article  PubMed  CAS  Google Scholar 

  74. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997; 126:32–5.

    PubMed  CAS  Google Scholar 

  75. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89:5454–61.

    Article  PubMed  CAS  Google Scholar 

  76. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28:111–33, vii.

    Article  PubMed  CAS  Google Scholar 

  77. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:2562–8.

    Article  PubMed  CAS  Google Scholar 

  78. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327:951–3.

    Article  PubMed  CAS  Google Scholar 

  79. Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002; 13:251–7.

    Article  PubMed  CAS  Google Scholar 

  80. Pasquali R, Gambineri A. Role of changes in dietary habits in polycystic ovary syndrome. Reprod Biomed Online 2004; 8:431–9.

    Article  PubMed  Google Scholar 

  81. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:812–9.

    Article  PubMed  CAS  Google Scholar 

  82. Holte J. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Baillieres Clin Endocrinol Metab 1996; 10:221–47.

    Article  PubMed  CAS  Google Scholar 

  83. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84:1470–4.

    Article  PubMed  CAS  Google Scholar 

  84. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998; 13:1502–5.

    Article  PubMed  CAS  Google Scholar 

  85. Clark AM, Ledger W, Galletly C, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995; 10:2705–12.

    PubMed  CAS  Google Scholar 

  86. Andersen P, Seljeflot I, Abdelnoor M, et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995; 44:611–6.

    Article  PubMed  CAS  Google Scholar 

  87. Franks S, Robinson S, Willis DS. Nutrition, insulin and polycystic ovary syndrome. Rev Reprod 1996; 1:47–53.

    Article  PubMed  CAS  Google Scholar 

  88. Moran LJ, Noakes M, Clifton PM, et al. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J Clin Endocrinol Metab 2004; 89:3337–44.

    Article  PubMed  CAS  Google Scholar 

  89. NIH. National Institutes of Health. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: Executive Summary. Am J Clin Nutr 68(4): 899–917.

    Google Scholar 

  90. Brinkworth GD, Noakes M, Keogh JB, Luscombe ND, Wittert GA, Clifton PM. Long-term effects of a high-protein, low-carbohydrate diet on weight control and cardiovascular risk markers in obese hyperinsulinemic subjects. Int J Obes Relat Metab Disord 2004; 28:661–70.

    Article  PubMed  CAS  Google Scholar 

  91. Howard BV, Manson JE, Stefanick ML, et al. Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA 2006; 295:39–49.

    Article  PubMed  CAS  Google Scholar 

  92. Barzel US, Massey LK. Excess dietary protein can adversely affect bone. J Nutr 1998; 128:1051–3.

    PubMed  CAS  Google Scholar 

  93. Calvo MS, Bell RR, Forbes RM. Effect of protein-induced calciuria on calcium metabolism and bone status in adult rats. J Nutr 1982; 112:1401–13.

    PubMed  CAS  Google Scholar 

  94. Monro J. Redefining the glycemic index for dietary management of postprandial glycemia. J Nutr 2003; 133:4256–8.

    PubMed  CAS  Google Scholar 

  95. Brand-Miller JC. Glycemic load and chronic disease. Nutr Rev 2003; 61:S49–55.

    Article  PubMed  Google Scholar 

  96. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol 2006; 154:141–5.

    Article  PubMed  CAS  Google Scholar 

  97. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 2003; 18:2289–93.

    Article  PubMed  Google Scholar 

  98. Cronin L, Guyatt G, Griffith L, et al. Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 1998; 83:1976–87.

    Article  PubMed  CAS  Google Scholar 

  99. Galletly C, Clark A, Tomlinson L, Blaney F. A group program for obese, infertile women: weight loss and improved psychological health. J Psychosom Obstet Gynaecol 1996; 17:125–8.

    Article  PubMed  CAS  Google Scholar 

  100. Nestler JE. Should patients with polycystic ovarian syndrome be treated with metformin? an enthusiastic endorsement. Hum Reprod 2002; 17:1950–3.

    Article  PubMed  CAS  Google Scholar 

  101. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003:CD003053.

    Google Scholar 

  102. Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005; 54:2404–14.

    Article  PubMed  Google Scholar 

  103. Norman RJ, Wu R, Stankiewicz MT. 4: Polycystic ovary syndrome. Med J Aust 2004; 180:132–7.

    PubMed  Google Scholar 

  104. Nestler JE. Metformin and the polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86:1430.

    Article  PubMed  CAS  Google Scholar 

  105. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85:2767–74.

    Article  PubMed  CAS  Google Scholar 

  106. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86:1626–32.

    Article  PubMed  CAS  Google Scholar 

  107. Yilmaz M, Biri A, Karakoc A, et al. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest 2005; 28:1003–8.

    PubMed  CAS  Google Scholar 

  108. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod 2006; 21:1400–7.

    Google Scholar 

  109. Yilmaz M, Karakoc A, Toruner FB, et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 2005; 21:154–60.

    Article  PubMed  CAS  Google Scholar 

  110. Ortega-Gonzalez C, Luna S, Hernandez L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:1360–5.

    Article  PubMed  CAS  Google Scholar 

  111. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89:3835–40.

    Article  PubMed  CAS  Google Scholar 

  112. Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 2004; 82 Suppl 3:1193–7.

    Article  PubMed  CAS  Google Scholar 

  113. Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev 2003:CD001125.

    Google Scholar 

  114. Cibula D, Fanta M, Vrbikova J, et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod 2005; 20:180–4.

    Article  PubMed  CAS  Google Scholar 

  115. Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999; 84:1304–10.

    Article  PubMed  CAS  Google Scholar 

  116. O'Brien RC, Cooper ME, Murray RM, Seeman E, Thomas AK, Jerums G. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism. J Clin Endocrinol Metab 1991; 72:1008–13.

    Article  PubMed  Google Scholar 

  117. Thys-Jacobs S, Donovan D, Papadopoulos A, Sarrel P, Bilezikian JP. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids 1999; 64:430–5.

    Article  PubMed  CAS  Google Scholar 

  118. Pasquali R, Cantobelli S, Vicennati V, et al. Nitrendipine treatment in women with polycystic ovarian syndrome: evidence for a lack of effects of calcium channel blockers on insulin, androgens, and sex hormone-binding globulin. J Clin Endocrinol Metab 1995; 80:3346–50.

    Article  PubMed  CAS  Google Scholar 

  119. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91:492–7.

    Article  PubMed  CAS  Google Scholar 

  120. Rabelo Acevedo M, Vick MR. Association between the polycystic ovary syndrome and the metabolic syndrome in Puerto Rico. P R Health Sci J 2005; 24:203–6.

    PubMed  Google Scholar 

  121. Sam S, Legro RS, Bentley-Lewis R, Dunaif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:4797–802.

    Article  PubMed  CAS  Google Scholar 

  122. Vrbikova J, Vondra K, Cibula D, Dvorakova K, Stanicka S, Sramkova D, Sindelka G, Hill M, Bendlova B, Skrha J. Metabolic syndrome in young Czech women with polycystic ovary syndrome. Hum Reprod 2005; 20:3328–32.

    Article  PubMed  CAS  Google Scholar 

  123. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 2005; 20:2409–13.

    Article  PubMed  Google Scholar 

  124. Korytkowski MT, Mokan M, Horwitz MJ, Berga SL. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrin Metab 1995; 80:3327–34.

    Article  CAS  Google Scholar 

  125. Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 1998; 13:2706–11.

    PubMed  CAS  Google Scholar 

  126. Armstrong VL, Wiggam MI, Ennis CN, Sheridan B, Traub AI, Atkinson AB, Bell PM. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate. Q J Med 2001; 94:31–7.

    CAS  Google Scholar 

  127. Vrbikova J, Stanicka S, Dvorakova K, Hill M, Vondra K, Bendlova B, Starka L. Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjunction with peroral cyproterone acetate in women with polycystic ovary syndrome. Eur J Endocrinol 2004; 150:215–23.

    Article  PubMed  CAS  Google Scholar 

  128. Guido M, Romualdi D, Guilliani M, Suriano R, Salvaggi L, Apa R, Lanzone A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004; 89:2817–23.

    Article  PubMed  CAS  Google Scholar 

  129. Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycysticovary syndrome. Hum Reprod Update 2005; 11:277–91.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Robert J. Norman MD PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anneloes E. Ruifrok
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lisa J. Moran PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rebecca L. Robker PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University, Chicago, IL

    Andrea Dunaif MD

  2. Department of Reproductive Medicine, University of California, San Diego School of Medicine, La Jolla, CA

    R. Jeffrey Chang MD

  3. Institute of Reproductive and Developmental Biology, Imperial College London, London, UK

    Stephen Franks MD, FMEDSCI

  4. Department of Ob/Gyn, Penn State College of Medicine, Hershey, PA

    Richard S. Legro MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press

About this chapter

Cite this chapter

Norman, R.J., Ruifrok, A.E., Moran, L.J., Robker, R.L. (2008). Recommended Therapies for Metabolic Defects in Polycystic Ovary Syndrome. In: Dunaif, A., Chang, R.J., Franks, S., Legro, R.S. (eds) Polycystic Ovary Syndrome. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-108-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-108-6_16

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-831-7

  • Online ISBN: 978-1-59745-108-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation